Phase II

Pharmacopeia shares rise on blood pressure data

admin — Fri, 16 May 2008 06:59:54 -0400

Pharmacopeia's shares were up today on trial results for PS433540, a hypertension drug. Data showed 'significant' blood pressure reductions in a Phase IIa study in patients with mild to moderate Read more...

Palatin slashes staff, dumps research program

admin — Wed, 14 May 2008 06:59:58 -0400

Palatin Technologies is cutting about a third of its workforce and dumping one of its lead development programs--an effort to find a better tolerated successor to sildenafil. After studying research Read more...

Intercell snaps up Iomai in $189M deal

admin — Tue, 13 May 2008 06:59:57 -0400

The little Maryland-based vaccine developer Iomai, which has posted some impressive data on a new therapy for Read more...

BMS inks $227M collaboration deal with KAI

admin — Tue, 13 May 2008 06:59:55 -0400

South San Francisco-based KAI Pharmaceuticals is getting a $25 million boost from Bristol-Myers Squibb---its upfront payment for a collaboration on KAI-9803, an experimental therapy to reduce the Read more...

Merck turns to Ranbaxy for $100M R&D effort

admin — Mon, 12 May 2008 06:59:58 -0400

India's Ranbaxy has flexed its research muscles once again, this time signing a five-year pact with Merck to develop new anti-infectives. Ranbaxy, which received an undisclosed upfront payment, says Read more...

NicOx shares plunge on Pfizer trial failure

admin — Tue, 06 May 2008 06:59:58 -0400

Shares of France's NicOx tumbled 38 percent after Pfizer announced that it would not advance their Read more...

SPOTLIGHT: Epix wins $7.5M milestone

admin — Mon, 05 May 2008 06:59:53 -0400

Epix Pharmaceuticals says it's due a $7.5 million milestone payment from GSK now that it's launched a Phase IIb trial of a new therapy for Alzheimer's. Researchers say the therapy could one day be Read more...

Pfizer builds plant, creates jobs in Ireland

admin — Fri, 02 May 2008 06:59:58 -0400

Pfizer has finally confirmed earlier reports about its plan to Read more...

Roche expands Memory pact

admin — Fri, 02 May 2008 06:59:55 -0400

Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' drug candidate, MEM 3454, for various neurological and psychiatric disorders. Memory gets a $6 million Read more...

Critical Therapeutics, Cornerstone to merge

admin — Fri, 02 May 2008 06:59:54 -0400

Critical Therapeutics is merging with Cornerstone Read more...